CPT® Code 80408

1. Indications

The aldosterone suppression evaluation panel is indicated for patients suspected of having primary and/or secondary hyperaldosteronism. The following conditions and symptoms may warrant this evaluation:

• Primary Hyperaldosteronism - Characterized by elevated aldosterone levels, sodium retention, potassium depletion, and hypertension, often resulting from adrenal tumors or hyperplasia.
• Secondary Hyperaldosteronism - Typically associated with elevated renin levels, this condition can arise from renal artery stenosis, congestive heart failure, cirrhosis, kidney disease, or preeclampsia.
• Symptoms of Hyperaldosteronism - Patients may present with urinary frequency, increased thirst, fatigue, muscle weakness or cramping, palpitations, and headaches, which can prompt further investigation into aldosterone and renin levels.

2. Procedure

The procedure for the aldosterone suppression evaluation panel involves several critical steps to ensure accurate measurement of aldosterone and renin levels:

• Step 1: Patient Preparation - Prior to the test, patients must follow a normal sodium diet (100-200 mEq/day) for three days and refrain from any medications that could affect the renin-aldosterone system. This preparation is essential for obtaining reliable baseline measurements.
• Step 2: Positioning and Baseline Blood Draw - Depending on the physician's specifications, the patient may need to be in a supine or upright position. For a supine test, the baseline blood draw should occur between 8 and 10 a.m. after the patient has been supine for at least two hours. If the test is ordered in the upright position, the blood draw must be performed before noon, with the patient sitting or standing for at least two hours prior to the draw.
• Step 3: Establishing IV Line - An intravenous (IV) line is established as a separate reportable procedure. Blood samples for measuring baseline aldosterone and renin levels can be drawn from this IV line or through a separately reportable venipuncture.
• Step 4: Sodium Chloride Infusion - An IV infusion of isotonic sodium chloride (0.9% NaCl) is initiated at a rate of 500 mL/hour for a total duration of four hours, resulting in a total volume of 2 liters administered to the patient.
• Step 5: Post-Infusion Blood Sample - At the conclusion of the sodium chloride infusion, a second blood sample is obtained to measure the post-infusion levels of aldosterone and renin. This allows for the assessment of how these hormone levels change in response to the infusion.
• Step 6: Laboratory Testing - The serum or plasma samples collected are then tested using quantitative radioimmunoassay or quantitative immunoradiometry to determine the levels of aldosterone and renin.

3. Post-Procedure

After the aldosterone suppression evaluation panel is completed, patients may be monitored for any immediate reactions to the sodium chloride infusion. There are typically no specific post-procedure care requirements, but patients should be advised to resume normal activities unless otherwise directed by their physician. The results of the test will be analyzed and interpreted by the healthcare provider, who will discuss the findings with the patient and determine any necessary follow-up actions based on the results.